FI113337B - Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi - Google Patents
Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi Download PDFInfo
- Publication number
- FI113337B FI113337B FI955215A FI955215A FI113337B FI 113337 B FI113337 B FI 113337B FI 955215 A FI955215 A FI 955215A FI 955215 A FI955215 A FI 955215A FI 113337 B FI113337 B FI 113337B
- Authority
- FI
- Finland
- Prior art keywords
- weight
- oxybutynin
- sustained release
- process according
- examples
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20641694 | 1994-03-04 | ||
US08/206,416 US5399359A (en) | 1994-03-04 | 1994-03-04 | Controlled release oxybutynin formulations |
US9402926 | 1994-03-18 | ||
PCT/US1994/002926 WO1995023593A1 (en) | 1994-03-04 | 1994-03-18 | Controlled release oxybutynin formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
FI955215A0 FI955215A0 (fi) | 1995-11-01 |
FI955215A FI955215A (fi) | 1995-11-01 |
FI113337B true FI113337B (fi) | 2004-04-15 |
Family
ID=22766272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI955215A FI113337B (fi) | 1994-03-04 | 1995-11-01 | Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi |
Country Status (15)
Country | Link |
---|---|
US (1) | US5399359A (pt) |
EP (1) | EP0700284B1 (pt) |
JP (2) | JP3699117B2 (pt) |
CN (1) | CN1111404C (pt) |
AT (1) | ATE222753T1 (pt) |
AU (1) | AU676556B2 (pt) |
CA (1) | CA2161103C (pt) |
DE (1) | DE69431247T2 (pt) |
DK (1) | DK0700284T3 (pt) |
ES (1) | ES2180574T3 (pt) |
FI (1) | FI113337B (pt) |
HU (1) | HUT72981A (pt) |
IL (1) | IL112637A (pt) |
PT (1) | PT700284E (pt) |
WO (1) | WO1995023593A1 (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
WO1996012477A1 (en) * | 1994-10-21 | 1996-05-02 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
US6124355A (en) * | 1995-05-22 | 2000-09-26 | Guittard; George V. | Oxybutynin therapy |
AU2068797A (en) * | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
ES2141044B1 (es) * | 1997-02-26 | 2001-02-01 | Alza Corp | Terapia con oxibutinina. |
US20040062799A1 (en) * | 1997-09-29 | 2004-04-01 | Ayer Atul D. | Therapeutic composition and delivery system for administering drug |
AR018321A1 (es) * | 1998-03-26 | 2001-11-14 | Alza Corp | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. |
US6087396A (en) * | 1998-10-05 | 2000-07-11 | Situs Corporation | Oxybutynin formulations and method of use |
JP3893058B2 (ja) * | 1999-09-30 | 2007-03-14 | ペンウェスト ファーマシューティカルズ カンパニー | 高度に可溶性の薬物のための徐放性マトリックス系 |
US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
JP2004529902A (ja) * | 2001-03-13 | 2004-09-30 | ペンウェスト ファーマシューティカルズ カンパニー | グルココルチコステロイドを含有する時間治療(chronotherapeutic)投与形態 |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
WO2003004030A1 (en) * | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oxymorphone controlled release formulations |
JP2005523876A (ja) * | 2001-09-26 | 2005-08-11 | ペンウェスト ファーマシューティカルズ カンパニー | 乱用の可能性が低減したオピオイド製剤 |
US20040265381A1 (en) * | 2001-10-08 | 2004-12-30 | Shanghvi Dilip S. | Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma |
DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US8329217B2 (en) * | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
EP1549296A4 (en) * | 2002-08-02 | 2006-08-09 | Penwest Pharmaceuticals Co | METFORMIN FORMULATIONS WITH DELAYED RELEASE |
CA2532714C (en) * | 2003-08-04 | 2010-11-16 | Kyorin Pharmaceutical Co., Ltd. | Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide |
KR100782918B1 (ko) * | 2003-09-19 | 2007-12-07 | 펜웨스트 파머슈티칼즈 컴파니 | 지연 방출성 제형 |
AU2004273958A1 (en) * | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
JP5610663B2 (ja) * | 2003-11-04 | 2014-10-22 | スパーナス ファーマシューティカルズ インコーポレイテッド | トロスピウムの1日1回剤形 |
US20050287185A1 (en) * | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
EP2208496A1 (en) * | 2004-08-25 | 2010-07-21 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
ATE512760T1 (de) | 2005-03-15 | 2011-07-15 | Htc Sweden Ab | Verfahren zur pflege einer harten, glatten, ein polymermaterial beinhaltenden oberfläche eines fussbodens |
US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
EP3545958B1 (en) | 2006-01-05 | 2024-07-10 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
US8124598B2 (en) * | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
AU2008272923A1 (en) * | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
US20090076144A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched bazedoxifene |
CN102170874A (zh) | 2008-08-06 | 2011-08-31 | 高思福斯中心(控股)有限公司 | 治疗精神病学障碍的组合物和方法 |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
BR112012022797A2 (pt) * | 2010-03-09 | 2018-02-20 | Alkermes Pharma Ireland Ltd | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool |
US20130172411A1 (en) * | 2010-03-22 | 2013-07-04 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
WO2013130411A1 (en) | 2012-02-27 | 2013-09-06 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
US9452135B2 (en) | 2012-03-20 | 2016-09-27 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
US20150133516A1 (en) | 2013-11-13 | 2015-05-14 | Brian K. Adams | Methods and Compositions for Treating ADHD |
KR102452254B1 (ko) | 2014-11-14 | 2022-10-11 | 에센셜리스 인코포레이티드 | 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법 |
US20180362974A1 (en) | 2015-07-02 | 2018-12-20 | University Of Louisville Research Foundation, Inc. | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER |
DE102015014581A1 (de) * | 2015-11-12 | 2017-05-18 | Nele Schmidt | Prolamine enthaltende Gele, Verfahren zu ihrer Herstellung und ihre Verwendung |
JP2017100971A (ja) * | 2015-11-30 | 2017-06-08 | 株式会社ファンケル | 錠剤 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4303691A (en) * | 1977-11-09 | 1981-12-01 | Anderson, Clayton & Co. | Proteinaceous food product |
US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
JPS5630485A (en) * | 1979-08-21 | 1981-03-27 | Sansho Kk | Heat insulation composition for heating and cooling |
BE902605A (fr) * | 1985-06-06 | 1985-09-30 | Therabel Res S A N V | Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition. |
US4795642A (en) * | 1986-05-01 | 1989-01-03 | Pharmacaps, Inc. | Gelatin-encapsulated controlled-release composition |
US4784857A (en) * | 1986-06-03 | 1988-11-15 | Smith And Nephew Associated Companies Plc | Drug delivery device, its preparation and use |
GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
DE3714074A1 (de) * | 1987-04-28 | 1988-11-10 | Hoechst Ag | Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage |
US4824675A (en) * | 1987-07-13 | 1989-04-25 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
US4857331A (en) * | 1988-03-31 | 1989-08-15 | Warner-Lambert Company | Sugarless pectin delivery system |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
US5207932A (en) * | 1989-07-20 | 1993-05-04 | Chubb National Foam, Inc. | Alcohol resistant aqueous film forming firefighting foam |
US5271943A (en) * | 1989-10-27 | 1993-12-21 | Scott Health Care | Wound gel compositions containing sodium chloride and method of using them |
US5215756A (en) * | 1989-12-22 | 1993-06-01 | Gole Dilip J | Preparation of pharmaceutical and other matrix systems by solid-state dissolution |
US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
JPH04273818A (ja) * | 1991-02-28 | 1992-09-30 | Kissei Pharmaceut Co Ltd | 経皮投与製剤 |
HU209251B (en) * | 1992-03-13 | 1994-04-28 | Synepos Ag | Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons |
ES2137261T3 (es) * | 1992-05-13 | 1999-12-16 | Alza Corp | Administracion transdermica de oxibutinina. |
JP2646170B2 (ja) * | 1992-06-24 | 1997-08-25 | 日本ヘキスト・マリオン・ルセル株式会社 | 徐放性塩酸オキシブチニン製剤 |
US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
-
1994
- 1994-03-04 US US08/206,416 patent/US5399359A/en not_active Expired - Lifetime
- 1994-03-18 AT AT94913918T patent/ATE222753T1/de not_active IP Right Cessation
- 1994-03-18 DE DE69431247T patent/DE69431247T2/de not_active Expired - Fee Related
- 1994-03-18 AU AU65888/94A patent/AU676556B2/en not_active Ceased
- 1994-03-18 ES ES94913918T patent/ES2180574T3/es not_active Expired - Lifetime
- 1994-03-18 DK DK94913918T patent/DK0700284T3/da active
- 1994-03-18 PT PT94913918T patent/PT700284E/pt unknown
- 1994-03-18 EP EP94913918A patent/EP0700284B1/en not_active Expired - Lifetime
- 1994-03-18 CA CA002161103A patent/CA2161103C/en not_active Expired - Fee Related
- 1994-03-18 HU HU9503054A patent/HUT72981A/hu unknown
- 1994-03-18 WO PCT/US1994/002926 patent/WO1995023593A1/en active IP Right Grant
- 1994-03-18 JP JP52288095A patent/JP3699117B2/ja not_active Expired - Fee Related
-
1995
- 1995-02-14 IL IL11263795A patent/IL112637A/en active IP Right Grant
- 1995-03-03 CN CN95100475A patent/CN1111404C/zh not_active Expired - Fee Related
- 1995-11-01 FI FI955215A patent/FI113337B/fi active
-
2004
- 2004-11-25 JP JP2004340786A patent/JP2005126444A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2161103A1 (en) | 1995-09-08 |
DE69431247T2 (de) | 2003-01-02 |
JP2005126444A (ja) | 2005-05-19 |
IL112637A0 (en) | 1995-05-26 |
US5399359A (en) | 1995-03-21 |
WO1995023593A1 (en) | 1995-09-08 |
CN1111404C (zh) | 2003-06-18 |
HUT72981A (en) | 1996-06-28 |
JPH09501445A (ja) | 1997-02-10 |
FI955215A0 (fi) | 1995-11-01 |
ES2180574T3 (es) | 2003-02-16 |
DE69431247D1 (de) | 2002-10-02 |
AU676556B2 (en) | 1997-03-13 |
HU9503054D0 (en) | 1996-01-29 |
EP0700284B1 (en) | 2002-08-28 |
CN1111507A (zh) | 1995-11-15 |
DK0700284T3 (da) | 2003-01-06 |
IL112637A (en) | 1999-01-26 |
JP3699117B2 (ja) | 2005-09-28 |
EP0700284A4 (en) | 1996-11-06 |
PT700284E (pt) | 2003-01-31 |
FI955215A (fi) | 1995-11-01 |
ATE222753T1 (de) | 2002-09-15 |
CA2161103C (en) | 1999-12-07 |
EP0700284A1 (en) | 1996-03-13 |
MX9501193A (es) | 1998-07-31 |
AU6588894A (en) | 1995-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI113337B (fi) | Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi | |
FI116450B (fi) | Menetelmä valmistaa metoprololin 24 tunnin valmistetta | |
FI118001B (fi) | Kerran päivässä suun kautta otettava metoprololiannosmuoto | |
KR100321489B1 (ko) | 고용량의불용성약물용서방성매트릭스 | |
US20060193912A1 (en) | Controlled release O-desmethylvenlafaxine formulations | |
JPH07165615A (ja) | 不溶性薬剤の持効性ヘテロ分散ヒドロゲル系 | |
MXPA95001193A (es) | Formulaciones de oxibutinina de liberacioncontrolada | |
MXPA96000024A (en) | Form of oral dosing of metoprolol one time | |
MXPA94008792A (en) | Sustained release formulations for 24 hours of metopro release | |
NZ500677A (en) | Sustained release dosage form, comprising a non-steroidal anti-inflammatory agent, and a sustained release carrier which comprises xantham gum, locust bean gum and a diluent |